Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin C Taylor

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Molecules (Basel, Switzerland)|June 21, 2020
Challenges in Chagas Disease Drug DevelopmentAmanda F Francisco, Shiromani Jayawardhana, Francisco Olmo, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2025
Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas diseaseShiromani Jayawardhana, Francisco Olmo, Amanda Fortes Francisco, et al.
Plos Pathogens|November 13, 2023
Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in miceShiromani Jayawardhana, Alexander I Ward, Amanda F Francisco, et al.
The Biochemical Journal|December 16, 2006
Mitochondrial superoxide radicals mediate programmed cell death in Trypanosoma cruzi: cytoprotective action of mitochondrial iron superoxide dismutase overexpressionLucía Piacenza, Florencia Irigoín, María Noel Alvarez, et al.
Nucleic Acids Research|September 25, 2010
Centromere-associated topoisomerase activity in bloodstream form Trypanosoma bruceiSamson O Obado, Christopher Bot, Maria C Echeverry, et al.
RSC Medicinal Chemistry|May 8, 2025
New <i>Trypanosoma brucei</i> acting derivatives incorporating 1-(4-phenyl)adamantane and 1-(4-phenoxyphenyl)adamantaneKonstantina Stavropoulou, Angeliki Kaimaki, Maria Nikolaou, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
Novel Lipophilic Hydroxamates Based on Spirocarbocyclic Hydantoin Scaffolds with Potent Antiviral and Trypanocidal ActivityVasiliki Pardali, Erofili Giannakopoulou, George Mpekoulis, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|September 1, 2018
Synthesis, anti-bacterial and anti-protozoal activities of amidinobenzimidazole derivatives and their interactions with DNA and RNAAndrea Bistrović, Luka Krstulović, Ivana Stolić, et al.
The Journal of Infectious Diseases|May 4, 2012
Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single populationAna Maria Mejia, Belinda S Hall, Martin C Taylor, et al.
Cellular Microbiology|April 10, 2014
Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infectionMichael D Lewis, Amanda Fortes Francisco, Martin C Taylor, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Molecules (Basel, Switzerland)|June 21, 2020
Challenges in Chagas Disease Drug DevelopmentAmanda F Francisco, Shiromani Jayawardhana, Francisco Olmo, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2025
Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas diseaseShiromani Jayawardhana, Francisco Olmo, Amanda Fortes Francisco, et al.
Plos Pathogens|November 13, 2023
Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in miceShiromani Jayawardhana, Alexander I Ward, Amanda F Francisco, et al.
The Biochemical Journal|December 16, 2006
Mitochondrial superoxide radicals mediate programmed cell death in Trypanosoma cruzi: cytoprotective action of mitochondrial iron superoxide dismutase overexpressionLucía Piacenza, Florencia Irigoín, María Noel Alvarez, et al.
Nucleic Acids Research|September 25, 2010
Centromere-associated topoisomerase activity in bloodstream form Trypanosoma bruceiSamson O Obado, Christopher Bot, Maria C Echeverry, et al.
RSC Medicinal Chemistry|May 8, 2025
New <i>Trypanosoma brucei</i> acting derivatives incorporating 1-(4-phenyl)adamantane and 1-(4-phenoxyphenyl)adamantaneKonstantina Stavropoulou, Angeliki Kaimaki, Maria Nikolaou, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
Novel Lipophilic Hydroxamates Based on Spirocarbocyclic Hydantoin Scaffolds with Potent Antiviral and Trypanocidal ActivityVasiliki Pardali, Erofili Giannakopoulou, George Mpekoulis, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|September 1, 2018
Synthesis, anti-bacterial and anti-protozoal activities of amidinobenzimidazole derivatives and their interactions with DNA and RNAAndrea Bistrović, Luka Krstulović, Ivana Stolić, et al.
The Journal of Infectious Diseases|May 4, 2012
Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single populationAna Maria Mejia, Belinda S Hall, Martin C Taylor, et al.
Cellular Microbiology|April 10, 2014
Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infectionMichael D Lewis, Amanda Fortes Francisco, Martin C Taylor, et al.
Pageof 10